News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|November 6, 2024

Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

Author(s)Nicholas J. Silvestri, MD, FAAN, Ali Habib, MD, Neelam Goyal, MD

Key Takeaways

Combination therapy in gMG is used for patients with severe symptoms or inadequate response to monotherapy, enhancing treatment efficacy.
Targeted treatments have revolutionized the management of newly diagnosed gMG patients, enabling more personalized therapeutic strategies.
The decision between conventional and advanced treatments is influenced by disease severity, patient response, and the availability of targeted therapies.

SHOW MORE

Panelists discuss how they approach combination therapy in generalized myasthenia gravis (gMG), including patient selection and timing, while also examining how the availability of newer targeted treatments has influenced their approach to managing newly diagnosed patients.

Episodes in this series

EP. 1 Generalized Myasthenia Gravis Presentation and Diagnosis

EP. 1 Generalized Myasthenia Gravis Presentation and Diagnosis

EP. 2 Generalized Myasthenia Gravis Classification and Treatment Strategy

EP. 2 Generalized Myasthenia Gravis Classification and Treatment Strategy

EP. 3 Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

EP. 3 Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

EP. 4 Outcome Measures in Generalized Myasthenia Gravis

EP. 4 Outcome Measures in Generalized Myasthenia Gravis

EP. 5 Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

EP. 5 Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

EP. 6 Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

EP. 6 Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

EP. 7 Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

EP. 7 Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

EP. 8 Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

EP. 8 Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

EP. 9 Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 9 Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 10 Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 10 Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 11 Use of Targeted Agents in Generalized Myasthenia Gravis

EP. 11 Use of Targeted Agents in Generalized Myasthenia Gravis

EP. 12 Management of Generalized Myasthenia Gravis in Pediatric Patients

EP. 12 Management of Generalized Myasthenia Gravis in Pediatric Patients

EP. 13 Unmet Needs in Generalized Myasthenia Gravis

EP. 13 Unmet Needs in Generalized Myasthenia Gravis

EP. 14 Generalized Myasthenia Gravis Pipeline

EP. 14 Generalized Myasthenia Gravis Pipeline

EP. 15 New Data from AANEM 2024 in Generalized Myasthenia Gravis

EP. 15 New Data from AANEM 2024 in Generalized Myasthenia Gravis

EP. 16 Clinical Pearls for Management of Generalized Myasthenia Gravis

EP. 16 Clinical Pearls for Management of Generalized Myasthenia Gravis

Video content above is prompted by the following:

Please discuss the use of combination therapy in gMG.
- For which patients and when would you consider use of combination therapy?
As more targeted treatments have become available, how has your approach to treatment of a newly diagnosed patient changed?
- When do you choose conventional vs advanced treatments?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME

4th Women in Neurology Conference

In-Person Event

4th Women in Neurology Conference

October 24-26, 2025

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

Carrie M. Hersh, DO, MSc, FAAN; Anna Shah, MD

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

James F. Howard Jr, MD; Nicholas J. Silvestri, MD, FAAN; Neelam Goyal, MD

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Alireza Atri, MD, PhD; Erik S. Musiek, MD, PhD; Malú Gámez Tansey, PhD

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings

Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

October 31, 2025

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Paul G. Auwaerter, MD, MBA; Paul P. Doghramji, MD, FAAFP; Aruna Subramanian, MD

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

In-Person + Virtual Event

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

November 21, 2025

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

John F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhD

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

James F. Howard Jr, MD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Testing D1 Receptor Modulator Glovadalen in Phase 2 Trial for Parkinson Disease: Milton Biagioni MD, CMD

Mechanistic Rationale Behind Amlenetug to Treat Multiple System Atrophy: Johan Luthman, PhD

Early Results Show Symptom Gains in First Patient Dosed With UX-DA001 Cell Therapy for Parkinson Disease

This Week on NeurologyLive® — October 20, 2025

RWJBarnabas and Rutgers Health Researchers Pursue Advanced Neurostimulation Technology to Treat Epileptic Seizures

© 2025 MJH Life Sciences^®

All rights reserved.